Spero Therapeutics Inc
SPRO2.335USD
+0.035+1.52%
交易中 （美東）報價延遲15分鐘
130.53M總市值
虧損本益比TTM
關於 Spero Therapeutics Inc 公司
Spero Therapeutics, Inc. 是一家臨牀階段的生物製藥公司。該公司專注於識別和開發罕見病和多重耐藥 (MDR) 細菌感染的新療法，這些療法尚未得到滿足。其主要候選產品 SPR720 是一種口服抗菌劑，用於治療一種罕見的孤兒病——非結核分枝桿菌 (NTM) 肺病。其合作伙伴指導的項目包括替比培南 HBr 和 SPR206。替比培南 HBr 旨在成爲口服卡巴培南類抗生素，用於治療某些細菌感染，這些細菌感染會導致由某些微生物引起的複雜性尿路感染 (cUTI)，包括腎盂腎炎，這些細菌感染適用於口服治療選擇有限的成年患者。SPR206 是一種直接作用的靜脈 (IV) 給藥候選產品，正在開發中，作爲在醫院環境中治療 MDR 革蘭氏陰性細菌感染的一種選擇。
公司簡介
公司代碼SPRO
公司名稱Spero Therapeutics Inc
上市日期Nov 02, 2017
CEOMs. Esther Rajavelu
員工數量32
證券類型Ordinary Share
年結日Nov 02
公司地址675 Massachusetts Ave Ste 14
城市CAMBRIDGE
上市交易所NASDAQ Global Select Consolidated
國家United States of America
郵編02139-3309
電話18572421600
網址https://sperotherapeutics.com/
公司代碼SPRO
上市日期Nov 02, 2017
CEOMs. Esther Rajavelu
公司高階主管
名稱
名稱/職務
職務
持股
持股變動
Dr. Ankit Mahadevia, M.D.
Dr. Ankit Mahadevia, M.D.
Non-Executive Director
Non-Executive Director
370.79K
+5.70%
Ms. Esther Rajavelu
Ms. Esther Rajavelu
President, Chief Executive Officer, Chief Financial Officer, Treasurer and Chief Business Officer
President, Chief Executive Officer, Chief Financial Officer, Treasurer and Chief Business Officer
228.68K
+423.52%
Mr. Timothy (Tim) Keutzer
Mr. Timothy (Tim) Keutzer
Chief Operating Officer
Chief Operating Officer
147.00K
-45.80%
Dr. Milind S. Deshpande, Ph.D.
Dr. Milind S. Deshpande, Ph.D.
Independent Director
Independent Director
91.45K
+27.99%
Ms. Kathleen Tregoning
Ms. Kathleen Tregoning
Independent Director
Independent Director
75.00K
+36.36%
Ms. Cynthia Smith
Ms. Cynthia Smith
Independent Director
Independent Director
75.00K
+36.36%
Mr. Frank E. Thomas, CPA
Mr. Frank E. Thomas, CPA
Independent Chairman of the Board
Independent Chairman of the Board
75.00K
+36.36%
Mr. Scott T. Jackson
Mr. Scott T. Jackson
Independent Director
Independent Director
--
--
Dr. Patrick Volkert Jo Vink, M.D.
Dr. Patrick Volkert Jo Vink, M.D.
Lead Independent Director
Lead Independent Director
--
--
Dr. John C. Pottage, Jr., M.D.
Dr. John C. Pottage, Jr., M.D.
Independent Director
Independent Director
--
--
名稱
名稱/職務
職務
持股
持股變動
Dr. Ankit Mahadevia, M.D.
Dr. Ankit Mahadevia, M.D.
Non-Executive Director
Non-Executive Director
370.79K
+5.70%
Ms. Esther Rajavelu
Ms. Esther Rajavelu
President, Chief Executive Officer, Chief Financial Officer, Treasurer and Chief Business Officer
President, Chief Executive Officer, Chief Financial Officer, Treasurer and Chief Business Officer
228.68K
+423.52%
Mr. Timothy (Tim) Keutzer
Mr. Timothy (Tim) Keutzer
Chief Operating Officer
Chief Operating Officer
147.00K
-45.80%
Dr. Milind S. Deshpande, Ph.D.
Dr. Milind S. Deshpande, Ph.D.
Independent Director
Independent Director
91.45K
+27.99%
Ms. Kathleen Tregoning
Ms. Kathleen Tregoning
Independent Director
Independent Director
75.00K
+36.36%
Ms. Cynthia Smith
Ms. Cynthia Smith
Independent Director
Independent Director
75.00K
+36.36%
收入明細
單位: USD更新時間: 7月6日 週日
單位: USD更新時間: 7月6日 週日
FY2025Q1
FY2024
FY2024Q4
FY2024Q3
FY2024Q2
FY2024Q1
FY2023
FY2023Q4
FY2023Q3
FY2023Q2
FY2023Q1
FY2022
FY2022Q4
FY2022Q3
FY2022Q2
FY2022Q1
FY2021
業務USD
名稱
營收
佔比
Collaboration Revenue Related Party
5.10M
86.81%
Grant Revenue
763.00K
12.99%
Collaboration Revenue
12.00K
0.20%
地區USD
名稱
營收
佔比
United States
5.87M
100.00%
業務
地區
業務USD
名稱
營收
佔比
Collaboration Revenue Related Party
5.10M
86.81%
Grant Revenue
763.00K
12.99%
Collaboration Revenue
12.00K
0.20%
股東統計
更新時間: 7月2日 週三
更新時間: 7月2日 週三
持股股東
股東類型
持股股東
持股股東
佔比
GSK plc
16.44%
Anson Funds Management LP.
6.79%
Pfizer Inc
4.23%
The Vanguard Group, Inc.
3.15%
Renaissance Technologies LLC
1.74%
Other
67.65%
持股股東
持股股東
佔比
GSK plc
16.44%
Anson Funds Management LP.
6.79%
Pfizer Inc
4.23%
The Vanguard Group, Inc.
3.15%
Renaissance Technologies LLC
1.74%
Other
67.65%
股東類型
持股股東
佔比
Corporation
20.66%
Hedge Fund
10.30%
Investment Advisor
5.26%
Investment Advisor/Hedge Fund
5.06%
Individual Investor
3.94%
Venture Capital
2.14%
Research Firm
0.14%
Other
52.50%
機構持股
更新時間: 7月1日 週二
更新時間: 7月1日 週二
報告期間
機構數
持股數
持股佔比
持股變動
2025Q2
114
26.81M
47.94%
-2.22M
2025Q1
116
27.38M
49.07%
-1.56M
2024Q4
125
27.51M
50.50%
+2.91M
2024Q3
143
24.19M
44.62%
-8.19M
2024Q2
160
25.74M
47.53%
-7.31M
2024Q1
203
25.36M
47.08%
-8.60M
2023Q4
209
24.88M
47.35%
-1.62M
2023Q3
223
24.62M
47.01%
-2.06M
2023Q2
230
24.99M
47.83%
-1.96M
2023Q1
242
24.74M
47.38%
-2.46M
查看更多
股東持股明細
名稱
持股數
佔比
持股變動
變動比例
公告日期
GSK plc
9.19M
16.44%
--
--
Mar 27, 2025
Anson Funds Management LP.
3.80M
6.79%
-40.95K
-1.07%
Mar 31, 2025
Pfizer Inc
2.36M
4.23%
--
--
Mar 31, 2025
The Vanguard Group, Inc.
1.76M
3.15%
--
--
Mar 31, 2025
Renaissance Technologies LLC
970.91K
1.74%
-134.68K
-12.18%
Mar 31, 2025
Alphabet, Inc.
889.98K
1.59%
--
--
Mar 31, 2025
Murchinson Ltd.
873.91K
1.56%
--
--
Mar 31, 2025
Acadian Asset Management LLC
871.21K
1.56%
-168.71K
-16.22%
Mar 31, 2025
Adar1 Capital Management LLC
801.28K
1.43%
--
--
Mar 31, 2025
Hamed (Kamal)
788.12K
1.41%
+211.66K
+36.72%
Feb 02, 2024
查看更多
持股ETF
更新時間: 8月2日 週六
更新時間: 8月2日 週六
機構名稱
佔比
Invesco NASDAQ Future Gen 200 ETF
0.52%
Avantis US Small Cap Equity ETF
0%
iShares Micro-Cap ETF
0%
Invesco NASDAQ Future Gen 200 ETF
佔比0.52%
Avantis US Small Cap Equity ETF
佔比0%
iShares Micro-Cap ETF
佔比0%
分紅派息
近5年累計派現
0.00
美元
公告日期
分紅計劃
股權登記日
現金發放日
除權除息日
暫無數據
拆合股
公告日期
類型
比率
暫無數據
公告日期
類型
比率
暫無數據
